Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlaxoSmithKline's Top Speaker Earned $99,375 in Second Quarter

Executive Summary

GlaxoSmithKline paid 3,700 U.S. physicians and other health care professionals $14.6 million during the second quarter of 2009. While GSK doled out less money than Lilly over a three-month period, its top recipients earned far more

You may also be interested in...



Sunshine Website Goes Live With Some Context Sought By Industry

CMS releases data on $3.5 billion worth of payments made by drug and device companies to physicians and teaching hospitals in the last five months of 2013; an additional 199,000 payment records were not disclosed.

Sunshine Act Hits Daylight Savings Time; PhRMA Seeks Extension For Physician Payment Reporting

Industry groups have asked HHS Secretary Kathleen Sebelius to give companies additional time to collect and report their payments to physicians and teaching hospitals since HHS has yet to establish the procedures for doing so.

Sunshine Act Hits Daylight Savings Time; PhRMA Seeks Extension For Physician Payment Reporting

Industry groups have asked HHS Secretary Kathleen Sebelius to give companies additional time to collect and report their payments to physicians and teaching hospitals since HHS has yet to establish the procedures for doing so.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel